Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee


To Purchase # 4307S

4307S 100 µl (10 western blots) $239.00
$ 0. 00


Find answers on our FAQs page.


Visit PhosphoSitePlus®

PTM information and tools available.


H Endogenous 50 Rabbit 

Western blot analysis of extracts from COS cells, untransfected or transfected with human ECGF1, and human THP-1 cells, using Thymidine Phosphorylase/ECGF1 (D69B12) Rabbit mAb.

Learn more about how we got this image

Product Usage Information

Application Dilutions
Western Blotting 1:1000
Immunoprecipitation 1:100

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

Thymidine Phosphorylase/ECGF1 (D69B12) Rabbit mAb detects endogenous levels of total TP/ECGF1 protein.

Species Reactivity: Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln370 of human thymidine phosphorylase/ECGF1 protein.

Thymidine phosphorylase (TP) is a platelet-derived endothelial cell growth factor (PD-ECGF) that catalyzes the formation of thymine and 2-deoxy-D-ribose-1-phosphate from thymidine and orthophosphate (1). This intracellular enzyme is capable of both promoting angiogenesis and inhibiting apoptosis. Thymidine phosphorylase catalytic activity is required for its angiogenic function (2,3). Increased expression of TP/PD-ECGF is seen in a wide variety of different solid tumors and inflammatory diseases and is often associated with poor prognosis (4,5). Alternatively, TP can activate fluorouracil derivative (DFUR) prodrugs and increase the antitumor activity of the related treatment (1,5). The use of thymidine phosphorylase as a cancer therapeutic target has been studied extensively, with emphasis on either inhibiting TP enzymatic activity or increasing enzyme induction with concomitant DFUR treatment (1,5).

1.  Rooseboom, M. et al. (2004) Pharmacol Rev 56, 53-102.

2.  Moghaddam, A. and Bicknell, R. (1992) Biochemistry 31, 12141-6.

3.  Furukawa, T. et al. (1992) Nature 356, 668.

4.  Toi, M. et al. (2005) Lancet Oncol 6, 158-66.

5.  Liekens, S. et al. (2007) Biochem Pharmacol 74, 1555-67.

Entrez-Gene Id 1890
Swiss-Prot Acc. P19971

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.